Xenical Diabetes Risk Reduction Data Added To Labeling

Roche weight loss drug adds data from the XENDOS trial showing ability to delay onset of type 2 diabetes in obese patients with impaired glucose tolerance. Change could help Roche increase reimbursement for Xenical.